Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295536 | 0.94 | KDR (0.61) | TP53TSHRMCHR1RAB9AMAPT | |
| SCHEMBL8348684 | 0.92 | MCHR1 (0.67) | TP53TSHRMCHR1RAB9AMAPT | |
| SCHEMBL21295375 | 0.91 | TP53 (0.66) | TP53TSHRRAB9AMAPTNPC1 | |
| SCHEMBL30743987 | 0.91 | TP53 (0.66) | TP53TSHRRAB9AMAPTNPC1 | |
| SCHEMBL19427494 | 0.87 | RAB9A (0.73) | TP53TSHRRAB9AMAPTNPC1 | |
| SCHEMBL21295417 | 0.87 | MCHR1 (0.59) | TP53TSHRMCHR1RAB9AMAPT | |
| SCHEMBL21295574 | 0.85 | NPC1 (0.76) | TP53TSHRRAB9AMAPTNPC1 | |
| SCHEMBL23292602 | 0.85 | TP53 (0.58) | TP53TSHRMCHR1RAB9AMAPT | |
| SCHEMBL14384694 | 0.85 | TTR (0.60) | MCHR1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL8350552 | 0.84 | KMT2A (0.72) | TP53RAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3759088-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2020-12-24 | — | — | US | disclosed |
| CN-111819172-A | Triazine derivatives for the treatment of neurotrophin-related disorders | 阿泽克制药公司 | 2020-10-23 | — | — | CN | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162702-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | TP53 2873/4885TSHR 144/4885MCHR1 321/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | TP53 2873/4885TSHR 144/4885MCHR1 321/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | TP53 2709/4885TSHR 123/4885MCHR1 317/4885 |
| US-20200399230-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | TP53 2709/4885TSHR 123/4885MCHR1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.